Ecuador: These 8 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Ecuador

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Ecuador: These 8 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Subscribe to access the full database, or Start Trial
Tradename	Ingredient	Estimated Entry Opportunity Date
KAZANO	alogliptin benzoate; metformin hydrochloride	2027-07-19
OSENI	alogliptin benzoate; pioglitazone hydrochloride	2027-02-01
PROMACTA	eltrombopag olamine	2027-05-03
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: Ecuador: These 8 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 19, 2027
Generic Entry Controlled by: Ecuador Patent SP109979

KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Ecuador Patent SP099608

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Ecuador Patent SP077628

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Ecuador Patent SP109957

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has eighty patent family members in thirty-seven countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch?

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Ecuador Patent SP099413

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch?

Generic name: allopurinol; lesinurad
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 27, 2027
Generic Entry Controlled by: Ecuador Patent SP10010310

DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug.

This drug has one hundred and forty-four patent family members in thirty-nine countries. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. There are twenty-two drug master file entries for this API. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch?

Generic name: lesinurad
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 27, 2027
Generic Entry Controlled by: Ecuador Patent SP10010310

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug.

This drug has one hundred and forty-four patent family members in thirty-nine countries. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Ecuador Patent SP099500

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch?

Generic name: paliperidone palmitate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 19, 2027
Generic Entry Controlled by: Ecuador Patent SP10010289

INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has thirty-eight patent family members in twenty-nine countries. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. There are thirty-eight drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the paliperidone palmitate profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 11, 2027
Generic Entry Controlled by: Ecuador Patent SP099772

VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug.

This drug has one hundred and twenty-one patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

When can RELISTOR (methylnaltrexone bromide) generic drug versions launch?

Generic name: methylnaltrexone bromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 04, 2026
Generic Entry Controlled by: Ecuador Patent SP088752

RELISTOR is a drug marketed by Salix Pharms and SalixThere are twelve patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-four patent family members in thirty-six countries. There has been litigation on patents covering RELISTOR

See drug price trends for RELISTOR.

The generic ingredient in RELISTOR is methylnaltrexone bromide. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the methylnaltrexone bromide profile page.